Zacks Research Issues Optimistic Forecast for NTLA Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Equities researchers at Zacks Research boosted their Q1 2025 EPS estimates for shares of Intellia Therapeutics in a note issued to investors on Tuesday, January 28th. Zacks Research analyst R. Department now forecasts that the company will post earnings of ($1.40) per share for the quarter, up from their previous estimate of ($1.43). The consensus estimate for Intellia Therapeutics' current full-year earnings is ($5.07) per share. Zacks Research also issued estimates for Intellia Therapeutics' Q2 2025 earnings at ($1.42) EPS, Q3 2025 earnings at ($1.43) EPS, Q4 2025 earnings at ($1.94) EPS, FY2025 earnings at ($6.20) EPS, Q1 2026 earnings at ($1.38) EPS, Q2 2026 earnings at ($1.26) EPS, Q3 2026 earnings at ($1.51) EPS, Q4 2026 earnings at ($2.44) EPS and FY2026 earnings at ($6.59) EPS.

A number of other research firms have also issued reports on NTLA. Robert W. Baird decreased their price objective on Intellia Therapeutics from $24.00 to $18.00 and set a "neutral" rating on the stock in a research note on Friday, October 25th. Barclays decreased their price target on Intellia Therapeutics from $76.00 to $55.00 and set an "overweight" rating on the stock in a research note on Friday, November 8th. Morgan Stanley cut Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and dropped their price objective for the stock from $56.00 to $11.00 in a report on Monday. Wedbush reissued a "neutral" rating and issued a $10.00 price target (down from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. Finally, Wells Fargo & Company dropped their target price on shares of Intellia Therapeutics from $70.00 to $60.00 and set an "overweight" rating on the stock in a report on Friday, January 10th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Intellia Therapeutics has an average rating of "Moderate Buy" and an average price target of $48.71.

Intellia Therapeutics Price Performance

NTLA stock opened at $10.51 on Friday. The stock's fifty day simple moving average is $12.41 and its two-hundred day simple moving average is $17.78. Intellia Therapeutics has a 1-year low of $9.25 and a 1-year high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.03. The company had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.28 million. The company's revenue for the quarter was down 24.1% on a year-over-year basis. During the same period last year, the firm posted ($1.38) earnings per share.

Institutional Investors Weigh In On Intellia Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. ARK Investment Management LLC boosted its position in shares of Intellia Therapeutics by 5.7% during the third quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company's stock worth $251,849,000 after buying an additional 659,651 shares during the period. State Street Corp increased its stake in Intellia Therapeutics by 17.9% during the third quarter. State Street Corp now owns 5,143,534 shares of the company's stock worth $105,700,000 after purchasing an additional 780,754 shares during the period. Geode Capital Management LLC boosted its stake in shares of Intellia Therapeutics by 2.2% in the third quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company's stock valued at $48,164,000 after purchasing an additional 49,367 shares during the period. FMR LLC increased its stake in Intellia Therapeutics by 5.0% during the 3rd quarter. FMR LLC now owns 2,339,522 shares of the company's stock worth $48,077,000 after buying an additional 111,104 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in Intellia Therapeutics by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company's stock worth $29,648,000 after buying an additional 98,865 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company's stock.

Insider Activity at Intellia Therapeutics

In other news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 28,735 shares of company stock worth $349,909 in the last 90 days. Corporate insiders own 3.20% of the company's stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.